| The Ness Center | |
|
23699 Quail Lane Mandeville LA 70448-7334 | |
| (985) 334-4040 | |
| (985) 626-6549 |
| Full Name | The Ness Center |
|---|---|
| Speciality | Clinic/Center |
| Location | 23699 Quail Lane, Mandeville, Louisiana |
| Authorized Official Name and Position | Tony Shir (OFFICER) |
| Authorized Official Contact | 8474524565 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| The Ness Center 7300 N Cicero Ave Suite 211 Lincolnwood IL 60712-1641 Ph: (224) 392-9889 | The Ness Center 23699 Quail Lane Mandeville LA 70448-7334 Ph: (985) 334-4040 |
| NPI Number | 1154855781 |
|---|---|
| Provider Enumeration Date | 04/20/2017 |
| Last Update Date | 06/15/2022 |
| Certification Date | 06/13/2022 |
| Medicare PECOS PAC ID | 9739457342 |
|---|---|
| Medicare Enrollment ID | O20170622000569 |
News Archive
Researchers have discovered two chemical compounds that effectively stop the growth of brain cancer cells and breast tumors, opening the way for potential new drugs to be developed.
Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.
There's a big difference between understanding coordination and actually building connectivity. In terms of building connectivity, several molecules have been identified that control this process and a lot has been learned from both genetic and biochemical research in a variety of different systems, particularly studies in the nematode C. elegans, the fruit fly Drosophila and mice.
Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.
A new California law that reclassifies some independent contractors as employees, requiring they be offered a range of benefits and worker protections, will likely expand health insurance coverage in the state, health policy experts say.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154855781 | NPI | - | NPPES |
| Provider Name | Jose Rodriguez |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1235399262 PECOS PAC ID: 4789727231 Enrollment ID: I20100205000061 |
News Archive
Researchers have discovered two chemical compounds that effectively stop the growth of brain cancer cells and breast tumors, opening the way for potential new drugs to be developed.
Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.
There's a big difference between understanding coordination and actually building connectivity. In terms of building connectivity, several molecules have been identified that control this process and a lot has been learned from both genetic and biochemical research in a variety of different systems, particularly studies in the nematode C. elegans, the fruit fly Drosophila and mice.
Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.
A new California law that reclassifies some independent contractors as employees, requiring they be offered a range of benefits and worker protections, will likely expand health insurance coverage in the state, health policy experts say.
› Verified 3 days ago
| Provider Name | Shanta Marie Smith |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427468503 PECOS PAC ID: 9436379922 Enrollment ID: I20141006000376 |
News Archive
Researchers have discovered two chemical compounds that effectively stop the growth of brain cancer cells and breast tumors, opening the way for potential new drugs to be developed.
Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.
There's a big difference between understanding coordination and actually building connectivity. In terms of building connectivity, several molecules have been identified that control this process and a lot has been learned from both genetic and biochemical research in a variety of different systems, particularly studies in the nematode C. elegans, the fruit fly Drosophila and mice.
Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.
A new California law that reclassifies some independent contractors as employees, requiring they be offered a range of benefits and worker protections, will likely expand health insurance coverage in the state, health policy experts say.
› Verified 3 days ago
| Provider Name | Karen M George |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1932498284 PECOS PAC ID: 9234445693 Enrollment ID: I20150831001077 |
News Archive
Researchers have discovered two chemical compounds that effectively stop the growth of brain cancer cells and breast tumors, opening the way for potential new drugs to be developed.
Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.
There's a big difference between understanding coordination and actually building connectivity. In terms of building connectivity, several molecules have been identified that control this process and a lot has been learned from both genetic and biochemical research in a variety of different systems, particularly studies in the nematode C. elegans, the fruit fly Drosophila and mice.
Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.
A new California law that reclassifies some independent contractors as employees, requiring they be offered a range of benefits and worker protections, will likely expand health insurance coverage in the state, health policy experts say.
› Verified 3 days ago
| Provider Name | Sureshkumar H Bhatt |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1922268994 PECOS PAC ID: 6608162730 Enrollment ID: I20160915001291 |
News Archive
Researchers have discovered two chemical compounds that effectively stop the growth of brain cancer cells and breast tumors, opening the way for potential new drugs to be developed.
Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.
There's a big difference between understanding coordination and actually building connectivity. In terms of building connectivity, several molecules have been identified that control this process and a lot has been learned from both genetic and biochemical research in a variety of different systems, particularly studies in the nematode C. elegans, the fruit fly Drosophila and mice.
Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.
A new California law that reclassifies some independent contractors as employees, requiring they be offered a range of benefits and worker protections, will likely expand health insurance coverage in the state, health policy experts say.
› Verified 3 days ago
| Provider Name | Graham L Spruiell |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1083683130 PECOS PAC ID: 9739197625 Enrollment ID: I20161109000481 |
News Archive
Researchers have discovered two chemical compounds that effectively stop the growth of brain cancer cells and breast tumors, opening the way for potential new drugs to be developed.
Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.
There's a big difference between understanding coordination and actually building connectivity. In terms of building connectivity, several molecules have been identified that control this process and a lot has been learned from both genetic and biochemical research in a variety of different systems, particularly studies in the nematode C. elegans, the fruit fly Drosophila and mice.
Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.
A new California law that reclassifies some independent contractors as employees, requiring they be offered a range of benefits and worker protections, will likely expand health insurance coverage in the state, health policy experts say.
› Verified 3 days ago
| Provider Name | Carol J Darr |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265514426 PECOS PAC ID: 2567894413 Enrollment ID: I20200323000248 |
News Archive
Researchers have discovered two chemical compounds that effectively stop the growth of brain cancer cells and breast tumors, opening the way for potential new drugs to be developed.
Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.
There's a big difference between understanding coordination and actually building connectivity. In terms of building connectivity, several molecules have been identified that control this process and a lot has been learned from both genetic and biochemical research in a variety of different systems, particularly studies in the nematode C. elegans, the fruit fly Drosophila and mice.
Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.
A new California law that reclassifies some independent contractors as employees, requiring they be offered a range of benefits and worker protections, will likely expand health insurance coverage in the state, health policy experts say.
› Verified 3 days ago
| Provider Name | Tyler Trenton Wansley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1962035964 PECOS PAC ID: 4486079050 Enrollment ID: I20200730001845 |
News Archive
Researchers have discovered two chemical compounds that effectively stop the growth of brain cancer cells and breast tumors, opening the way for potential new drugs to be developed.
Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.
There's a big difference between understanding coordination and actually building connectivity. In terms of building connectivity, several molecules have been identified that control this process and a lot has been learned from both genetic and biochemical research in a variety of different systems, particularly studies in the nematode C. elegans, the fruit fly Drosophila and mice.
Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.
A new California law that reclassifies some independent contractors as employees, requiring they be offered a range of benefits and worker protections, will likely expand health insurance coverage in the state, health policy experts say.
› Verified 3 days ago
| Provider Name | Sauntrice O'quin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194246686 PECOS PAC ID: 3870850563 Enrollment ID: I20201118000548 |
News Archive
Researchers have discovered two chemical compounds that effectively stop the growth of brain cancer cells and breast tumors, opening the way for potential new drugs to be developed.
Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.
There's a big difference between understanding coordination and actually building connectivity. In terms of building connectivity, several molecules have been identified that control this process and a lot has been learned from both genetic and biochemical research in a variety of different systems, particularly studies in the nematode C. elegans, the fruit fly Drosophila and mice.
Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.
A new California law that reclassifies some independent contractors as employees, requiring they be offered a range of benefits and worker protections, will likely expand health insurance coverage in the state, health policy experts say.
› Verified 3 days ago
| Provider Name | Chad W Trosclair |
|---|---|
| Provider Type | Practitioner - Addiction Medicine |
| Provider Identifiers | NPI Number: 1952556094 PECOS PAC ID: 4385076140 Enrollment ID: I20230914001777 |
News Archive
Researchers have discovered two chemical compounds that effectively stop the growth of brain cancer cells and breast tumors, opening the way for potential new drugs to be developed.
Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.
There's a big difference between understanding coordination and actually building connectivity. In terms of building connectivity, several molecules have been identified that control this process and a lot has been learned from both genetic and biochemical research in a variety of different systems, particularly studies in the nematode C. elegans, the fruit fly Drosophila and mice.
Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.
A new California law that reclassifies some independent contractors as employees, requiring they be offered a range of benefits and worker protections, will likely expand health insurance coverage in the state, health policy experts say.
› Verified 3 days ago
News Archive
Researchers have discovered two chemical compounds that effectively stop the growth of brain cancer cells and breast tumors, opening the way for potential new drugs to be developed.
Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.
There's a big difference between understanding coordination and actually building connectivity. In terms of building connectivity, several molecules have been identified that control this process and a lot has been learned from both genetic and biochemical research in a variety of different systems, particularly studies in the nematode C. elegans, the fruit fly Drosophila and mice.
Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.
A new California law that reclassifies some independent contractors as employees, requiring they be offered a range of benefits and worker protections, will likely expand health insurance coverage in the state, health policy experts say.
› Verified 3 days ago
Lurline Smith Mental Health Center Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 900 Wilkinson St, Mandeville, LA 70448 Phone: 985-624-4450 | |
C Hope Health Services Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1402 N Causeway Blvd, Apt. 608, Mandeville, LA 70471 Phone: 770-743-7055 | |
Northlake Behavioral Health System Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 23515 Hwy 190, Mandeville, LA 70448 Phone: 847-452-4585 Fax: 985-626-6559 | |
Northlake Medical Psychology And Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 215 Saint Ann Dr Ste 2, Mandeville, LA 70471 Phone: 601-946-1844 | |
Northshore Zen Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2000 N Causeway Blvd Ste B, Mandeville, LA 70471 Phone: 985-882-1322 Fax: 985-809-6909 | |
Lifenet Behavioral Health Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4070 Lonesome Rd, Suite B, Mandeville, LA 70448 Phone: 985-246-2600 Fax: 985-246-2601 | |
Michele Marie Mixon, Lcsw Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2244 11th St, Mandeville, LA 70471 Phone: 225-266-8122 |